

Drug Utilization Review Board

(DUR Board)

Meeting – July 9, 2008 @ 6:00 p.m.

Oklahoma Health Care Authority
4545 N. Lincoln Suite 124
Oklahoma City, Oklahoma 73105
Oklahoma Health Care Authority Board Room

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. McNeill, Chairman:

- 1. Call To Order**
 - A. Roll Call – Dr. Graham

Items to be presented by Dr. McNeill, Chairman:

- 2. Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Item

Items to be presented by Dr. McNeill, Chairman:

- 3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. May 14, 2008 DUR Minutes – Vote
 - B. May 15, 2008 DUR Recommendations Memorandum
 - C. Provider Correspondence

Items to be presented by Dr. Keast, Dr. McNeill, Chairman:

- 4. Update on DUR/MCAU Program – See Appendix B.**
 - A. Retrospective Drug Utilization Review for February 2008
 - B. Retrospective Drug Utilization Review for March 2008
 - C. Retrospective Drug Utilization Review Responses for November 2007
 - D. Retrospective Drug Utilization Review Responses for December 2007
 - E. Medication Coverage Activity Audit for May 2008
 - F. Medication Coverage Activity Audit for June 2008
 - G. Help Desk Activity Audit for May 2008
 - H. Help Desk Activity Audit for June 2008

Items to be presented by Dr. Keast, Dr. McNeill, Chairman:

- 5. Vote to Prior Authorize Osteoporosis Medications – See Appendix C.**
 - A. COP Recommendations

Items to be presented by Dr. Patel, Dr. McNeill, Chairman:

- 6. Vote to Prior Authorize Topical Antibiotics – See Appendix D.**
 - A. COP Recommendations

Items to be presented by Dr. Moore, Dr. McNeill, Chairman

7. **Vote to Prior Authorize Auralgan™ – See Appendix E.**
 - A. Product Summary
 - B. COP Recommendations

Items to be presented by Dr. Le, Dr. McNeill, Chairman

8. **Vote to Prior Authorize Plavix® 300mg – See Appendix F.**
 - A. COP Recommendations

Items to be presented by Dr. Le, Dr. Keast, Dr. McNeill, Chairman

9. **Vote to Prior Authorize Singulair® – See Appendix G.**
 - A. Product Summary
 - B. COP Recommendations

Items to be presented by Dr. Le, Dr. McNeill, Chairman

10. **Vote to Update Antidepressants PBPA Category and Vote to Prior Authorize Pristiq® – See Appendix H.**
 - A. Current Antidepressants Criteria
 - B. Utilization Review
 - C. COP Recommendations

Items to be presented by Dr. Patel, Dr. McNeill, Chairman

11. **30 Day Notice to Prior Authorize Voltaren® Gel – See Appendix I.**
 - A. Product Summary
 - B. COP Recommendations

Items to be presented by Dr. Le, Dr. McNeill, Chairman

12. **30 Day Notice to Prior Authorize Luvox CR® – See Appendix J.**
 - A. Product Summary
 - B. Cost Comparison
 - C. COP Recommendations

Items to be presented by Dr. Keast, Dr. McNeill, Chairman

13. **FDA and DEA Updates – See Appendix K.**

14. **Future Business**
 - A. Oral Antifungals Review
 - B. Qualaquin® Annual Review
 - C. ESA Review
 - D. Glaucoma Intervention Report
 - E. Hemophilia Review
 - F. New Product Reviews